Sanuwave Health, Inc. (OTCBB: SNWV) is developing and commercializing patented devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Sanuwave’s portfolio of regenerative medicine products and candidates are based on the company’s patented PACE technology for wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate, dermaPACE(R), is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. dermaPACE is currently under the U.S. FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. For more information, visit the company’s website at www.sanuwave.com